Histamine protects T cells and natural killer cells against oxidative stress

Journal of Interferon and Cytokine Research

Volumn 19, Issue 10, 1999, Pages 1135-1144

  Hansson, Markus ^a   Hermodsson, Svante ^a   Brune, Mats ^a   Mellqvist, Ulf Henrik ^a   Naredi, Peter ^b   Betten, Åsa ^a   Gehlsen, Kurt R ^c   Hellstrand, Kristoefer ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c Maxim Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE;

ANIMAL CELL; ARTICLE; HISTAMINE RELEASE; NATURAL KILLER CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD; ANTIGENS, CD95; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; APOPTOSIS; CYTOPROTECTION; HISTAMINE; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LIGANDS; MACROPHAGES; MONOCYTES; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES;

ANIMALIA;

EID: 0032739280     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999099313073     Document Type: Article

References (41)

1. MANTOVANI, A., BOTTAZZI, B., COLOTTA, F., SOZZANI, S., and RUCO, L. (1992). The origin and function of tumor-associated macrophages. Immunol. Today 13, 265-270.
2. ARMSTRONG, T.D., PULASKI, B.A., and OSTRAND-ROSENBERG, S. (1998). Tumor antigen presentation. Cancer Immunol. Immunother. 46, 70-74.
3. MATSUDA, M., PETERSSON, M., LENKEL, R., TAUPIN, J.L., MAGNUSSON, I., MELLSTEDT, H., ANDERSON, P., and KIESSLING, R. (1995). Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer 61, 765-772.
4. Mizoguchi, H., O'Shea, J.J., Longo, D.L., Loeffler, C.M., McVicar, D.W., and Ochoa, A.C. (1992). Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258, 1795-1798.
5. OTSUJI, M., KIMURA, Y., AOE, T., OKAMOTO, Y., and SAITO, T. (1996). Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. USA 93, 13119-13124.
6. KONO, K., SALAZAR-ONFRAY, F., PETERSSON, M., HANS- SON, J., MASUCCI, G., WASSERMAN, K., NAKAZAWA, T., ANDERSON, P., and KIESSLING, R. (1996). Hydrogen peroxide secreted by tumor-derived macrophages downmodulates signal-transducing zeta molecules and inhibits tumor-specific T cell and natural killer cell-mediated cytotoxicity. Eur. J. Immunol. 26, 1308-1313.
7. KIESSLING, R., KONO, K., PETERSSON, M., and WASSERMAN, K. (1996). Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Springer Semin. Immunopathol. 18, 227-242.
8. DOHLSTEN, M., LINDEN, O., HEDLUND, G., SJÖGKEN, H.O., DIAMANTSTEIN, T., and CARLSSON, R. (1986). Synergistic action of gamma interferon and catalase to reverse the suppressive effect of peritoneal macrophages on concanavalin A-induced lymphocyte proliferation. Scand. J. Immunol. 24, 49-58.
9. LINDEN, O., DOHLSTEN, M., BOKETOFT, A., HEDLUND, G., and SJÖGREN, H.-O. (1987). Catalase and lipopolysaccharide enhance proliferation in the rat mixed lymphocyte reaction. Scand. J. Immunol. 26, 223-228.
10. HELLSTRAND, K., ASEA, A., DAHLGREN, C., and HERMODSSON, S. (1994). Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J. Immunol. 153, 4940-4947.
11. HANSSON, M., ASEA, A., ERSSON, U., HERMODSSON, S., and HELLSTRAND, K. (1996). Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J. Immunol. 156, 42-47.
12. TRINCHIERI, G. (1989). Biology of natural killer cells. Adv. Immunol. 47, 187-376.
13. HAWKINS, M.J. (1993). Interleukin-2 antitumor and effector cell responses. Semin. Oncol. 20, 52-59.
14. BECKER, J.C., PANCOOK, J.D., GILLIES, S.D., FURUKAWA, K., and REISFELD, R.A. (1996). T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med. 183, 2361-2366.
15. BRUNDA, M.J., BELLANTONI, D., and SULICH, V. (1987). In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int. J. Cancer 40, 365-371.
16. WHITESIDE, T.L., VUJANOVIC, N.L., and HERBERMAN, R.B. (1998). Natural killer cells and tumor therapy. Curr. Top. Microbiol. Immunol. 230, 221-244.
17. LANIER, L.L., BUCK, D.W., RHODES, L., DING, A., EVANS, E., BARNEY, C., and PHILLIPS, J.H. (1998). Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen. J. Exp. Med. 167, 1572-1585.
18. LUNDQVIST, H., and DAHLGREN, C. (1996). Isoluminol-enhanced chemiluminescence: a sensitive method to study the release of Superoxide anion from human neutrophils. Free Radic. Biol. Med. 20, 785-792.
19. ALLEN, R.T., HUNTER, W.J., and AGRAWAL, D.K. (1997). Morphological and biochemical characterization and analysis of apoptosis. J. Pharmacol. Toxicol. Methods 37, 215-228.
20. BARHOUMI, R., BOWEN, J.A., STEIN, L.S., ECHOLS, J., and BURGHARDT, R.C. (1993). Concurrent analysis of intracellular glutathione content and gap junctional intercellular communication. Cytometry 14, 747-756.
21. KLEBANOFF, S.J. (1982). Oxygen dependent defence mechanisms of phagocytes. Adv. Host Def, Mech. 1, 111-151.
22. MIESEL, R., KURPISZ, M., and KROGER, H. (1996). Suppression of inflammatory arthritis by simultaneous inhibition of nitric oxide synthase and NADPH oxidase. Free. Radic. Biol. Med. 20, 75-81.
23. BUTTKE, T.M., and SANDSTROM, P.A. (1994). Oxidative stress as a mediator of apoptosis. Immunol. Today 15, 7-10.
24. DROGE, W., SCHULZE-OSTHOFF, K., MIHM, S., GALTER, D., SCHENK, H., ECK, H.P., ROTH, S., and GMUNDER, H. (1994). Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J 8, 1131-1138.
25. SLATER, A.F., STEFAN, C., NOBEL, I., VAN DEN DOBBELSTEEN, D.J., and ORRENIUS, S. (1995). Signalling mechanisms and oxidative stress in apoptosis. Toxicol. Lett. 82-83, 149-153.
26. ALDERSON, M.R., TOUGH, T.W., DAVIS-SMITH, BRADDY, S., FALK, B. SCHOOLEY, K.A., GOODWIN, R.G., SMITH, C.A., RAMSDELL, F., and LYNCH, D.H. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181, 71-77.
27. MEDVEDEV, A.E., JOHNSEN, A.C., HAUX, J., STEINKJER, B., EGEBERG, K., LYNCH, D.H., SUNDAN, A., and ESPEVIK, T. Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokine 9, 394-404.
28. BAUER, M.K.A., VOGT, M., LOS, M., SIEGEL, J., WESSELBORG, S., and SCHULZE-OSTHOFF, K. (1998). Role of reactive oxygen intermediates in activation-induced CD95 (APO-1/Fas) ligand expression. J. Biol. Chem. 273, 8048-8055.
29. DUMONT, A., HEHNER, S.P., HOFMANN, T.G., UEFFING, M., DROGE, W., and SCHMITZ, M.L. (1999). Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-kappaB. Oncogene 18, 747-757.
30. BOTTAZZI, B., WALTER, S., GOVINO, D., COLOTTA F., and MANTOVANI, A. (1992). Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth and susceptibility to IL-2 therapy of a murine melanoma. J. Immunol. 148, 1280-1285.
31. YIM, C.Y., HIBBS, J.B., McGREGOR, J.R., GALINSKY, R.E., and SAMLOWSKI, W.E. (1994). Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2. J. Immunol. 152, 5796-5805.
32. JOHANSSON, S., LANDSTRÖM, M., HELLSTRAND, K., and HENRIKSSON, R. (1998). The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation. Br. J. Cancer 77, 1213-1219.
33. ASEA, A., HERMODSSON, S., and HELLSTRAND K. (1996). Histaminergic regulation of natural killer-cell-mediated clearance of tumor cells in mice. Scand. J. Immunol. 43, 9-15.
34. HELLSTRAND, K., ASEA, A., and HERMODSSON, S. (1990). Role of histamine in natural killer cell-mediated resistance against tumor cells. J. Immunol. 145, 4365-4370.
35. ZEA, A.H., CURTI, B.D., LONGO, D.L., ALVORD, N.G., STROBL, S.L., MIZOGUCHI, H., CREEKMORE, S.P., OSHEA, J.J., POWERS, G.C., and URBA, W.J. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. 1, 1327-1335.
36. RABINOWICH, H., BANKS, M., REICHERT, T.E., LOGAN, T.F., KIRKWOOD, J.M., and WHITESIDE, T.L. (1996). Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin. Cancer Res. 2, 1263-1274.
37. WHITESIDE, T. (1998). Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects. Adv. Exp. Med. Biol. 451, 167-171.
38. HELLSTRAND, K., NAREDI, P., LINDNER, P., LUNDHOLM, K., RUDENSTAM, C.M., HERMODSSON, S., ASZTELY, M., and HAFSTROM, L. (1994). Histamine in immunotherapy of advanced melanoma: a pilot study. Cancer Immunol. Immunother. 39, 416-419.
39. BUGGINS, A.C., HIRST, W.J., PAGLIUCA, A., and MUFTI, G.J. (1998). Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. Br. J. Haematol. 100, 784-792.
40. HELLSTRAND, K., MELLGVIST, U.H., WALLHULT, E., CARNESKOG, J., KIMBY, E., CELSING, F., and BRUNE, M. (1997). Histamine and interleukin-2 in acute myelogenous leukemia. Leuk. Lymphoma 27, 429-438.
41. WALLHULT, E., MELLGVIST, U.H., CELSING, F., HELLSTRAND, K., NILSSON, B., SIMONSSON, B., and BRUNE, M. (1998). Safety and feasibility of IL-2 plus histamine dihydrochloride in AML patients in first or subsequent complete remission. Blood 92, 2533.